Latest News

Common multiple sclerosis drugs taken together do not reduce relapse risk

A recent clinical trial found that interferonβ-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Motivation explains disconnect between testing, real-life functioning for seniors

  • Novel technologies advance brain surgery to benefit patients

  • Mutated gene linked to both autism, intellectual disability

  • New concerns over top-selling blood thinning drug after investigation

  • Immune response may cause harm in brain injuries, disorders

  • New mechanism for neurodegeneration found

  • New tools help neuroscientists analyze 'big data'

  • Six new genetic risk factors for Parkinson's found

  • CEOs who motivate with 'fightin' words' shoot themselves in the foot

  • Knowledgeable consumers more likely to buy when given fewer options

  •